Format

Send to

Choose Destination
J Neuroinflammation. 2018 Aug 21;15(1):232. doi: 10.1186/s12974-018-1270-x.

High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats.

Author information

1
School of Medicine and Surgery, Experimental Neurology Unit and Milan Center for Neuroscience, University of Milano-Bicocca, via Cadore 48, 20900, Monza, MB, Italy. cristina.meregalli@unimib.it.
2
Kedrion S.p.A, Loc. Ai Conti, Castelvecchio Pascoli, Lucca, Italy.
3
School of Medicine and Surgery, Experimental Neurology Unit and Milan Center for Neuroscience, University of Milano-Bicocca, via Cadore 48, 20900, Monza, MB, Italy.
4
PhD program in Translational and Molecular Medicine (Dimet), University of Milano-Bicocca, Monza, Italy.
5
Clinical Chemistry Laboratory, S. Gerardo Hospital, Monza, Italy.
6
Young Against Pain group, Parma, Italy.
7
PhD program in Neuroscience, University of Milano-Bicocca, Monza, Italy.
8
Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, Monserrato, Italy.
9
Department of Neuroscience, Neurology Unit, University of Padova, Padova, Italy.

Abstract

BACKGROUND:

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a severe adverse effect in patients receiving antitumor agents, and no effective treatment is available. Although the mechanisms responsible for the development of CIPN are poorly understood, recent findings make neuroinflammation an attractive target to be investigated, particularly when neuropathic pain is a prominent feature such as after bortezomib administration. The aim of our study was to evaluate the effect of intravenous immunoglobulins (IVIg) delivery in chronic CIPN. The related neuro-immune aspects were investigated in a well-characterized rat model of bortezomib-induced peripheral neurotoxicity (BIPN).

METHODS:

After determination of a suitable schedule based on a preliminary pharmacokinetic pilot study, female Wistar rats were treated with IVIg 1 g/kg every 2 weeks. IVIg treatment was started at the beginning of bortezomib administration ("preventive" schedule), or once BIPN was already ensued after 4 weeks of treatment ("therapeutic" schedule). Neurophysiological and behavioral studies were performed to assess the extent of painful peripheral neurotoxicity induced by bortezomib, and these functional assessments were completed by pathologic examination of peripheral nerves and intraepidermal nerve fiber quantification (IENF). The role of the innate immune response in BIPN was investigated by immunochemistry characterization of macrophage infiltration in peripheral nerves.

RESULTS:

Both schedules of IVIg administration were able to significantly reduce bortezomib-induced heat and mechanical allodynia. Although these changes were not evidenced at the neurophysiological examination of peripheral nerves, they behavioral effects were paralleled in the animals treated with the preventive schedule by reduced axonopathy in peripheral nerves and significant protection from loss of IENF. Moreover, IVIg administration was very effective in reducing infiltration in peripheral nerves of macrophages with the M1, pro-inflammatory phenotype.

CONCLUSION:

Our results suggest a prominent role of neuroinflammation in BIPN and that IVIg might be considered as a possible safe and effective therapeutic option preventing M1 macrophage infiltration. However, since neuropathic pain is frequent also in other CIPN types, it also indicates the need for further investigation in other forms of CIPN.

KEYWORDS:

Allodynia; Bortezomib; Human intravenous immunoglobulin (IVIG); Neuroinflammation; Peripheral neurotoxicity

PMID:
30131066
PMCID:
PMC6103882
DOI:
10.1186/s12974-018-1270-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center